[1] Tang H, Zhou JF, Bai CM. The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease. Front Oncol, 2021; 11, 625872. doi:  10.3389/fonc.2021.625872
[2] Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol, 2022; 29, 3044−60. doi:  10.3390/curroncol29050247
[3] Zumla A, Raviglione M, Hafner R, et al. Tuberculosis. N Engl J Med, 2013; 368, 745−55. doi:  10.1056/NEJMra1200894
[4] Shen L, Gao Y, Liu YY, et al. PD-1/PD-L pathway inhibits M. tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci Rep, 2016; 6, 38362. doi:  10.1038/srep38362
[5] Hassan SS, Akram M, King EC, et al. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One, 2015; 10, e0137646. doi:  10.1371/journal.pone.0137646
[6] Liu KW, Wang DP, Yao C, et al. Increased tuberculosis incidence due to immunotherapy based on PD-1 and PD-L1 blockade: a systematic review and meta-analysis. Front Immunol, 2022; 13, 727220. doi:  10.3389/fimmu.2022.727220
[7] Barber DL, Mayer-Barber KD, Feng CG, et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol, 2011; 186, 1598−607.
[8] Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol, 2014; 32, 2595−603. doi:  10.1200/JCO.2013.54.8347
[9] Henson SM, Macaulay R, Riddell NE, et al. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8+ T-cell proliferation by distinct pathways. Eur J Immunol, 2015; 45, 1441−51. doi:  10.1002/eji.201445312
[10] Khan N, Vidyarthi A, Amir M, et al. T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol, 2017; 43, 133−41. doi:  10.1080/1040841X.2016.1185603